Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $62.17.

A number of research firms have recently weighed in on CLDX. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, July 30th. Stifel Nicolaus began coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price objective on the stock. Wolfe Research started coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, July 30th.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $34.78 on Wednesday. The firm’s 50 day moving average price is $36.74 and its two-hundred day moving average price is $39.07. The firm has a market cap of $2.29 billion, a PE ratio of -12.20 and a beta of 1.58. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities analysts anticipate that Celldex Therapeutics will post -2.39 EPS for the current fiscal year.

Insider Transactions at Celldex Therapeutics

In other Celldex Therapeutics news, VP Elizabeth Crowley sold 15,000 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $35.06, for a total transaction of $525,900.00. Following the completion of the sale, the vice president now directly owns 9,074 shares in the company, valued at $318,134.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Richard M. Wright sold 46,844 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $33.72, for a total value of $1,579,579.68. Following the sale, the vice president now owns 20,833 shares in the company, valued at $702,488.76. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Elizabeth Crowley sold 15,000 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $35.06, for a total transaction of $525,900.00. Following the transaction, the vice president now owns 9,074 shares of the company’s stock, valued at $318,134.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 266,332 shares of company stock worth $9,155,821. 3.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its stake in shares of Celldex Therapeutics by 19.2% in the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after buying an additional 1,044,728 shares during the period. Vanguard Group Inc. raised its holdings in Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after acquiring an additional 604,251 shares in the last quarter. Eventide Asset Management LLC lifted its position in shares of Celldex Therapeutics by 126.9% in the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after acquiring an additional 2,030,013 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after purchasing an additional 2,664,915 shares in the last quarter. Finally, Bellevue Group AG increased its position in shares of Celldex Therapeutics by 15.7% during the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock valued at $117,374,000 after purchasing an additional 380,319 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.